Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) EPS (Diluted) : $-12.75 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings EPS (Diluted)?

Sonnet BioTherapeutics Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.75.

Sonnet BioTherapeutics Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.75.

Sonnet BioTherapeutics Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.71.

During the past 3 years, the average EPS without NRIGrowth Rate was 78.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Sonnet BioTherapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 78.90% per year. The lowest was 18.80% per year. And the median was 48.85% per year.

Sonnet BioTherapeutics Holdings EPS (Diluted) Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings EPS (Diluted) Chart

Sonnet BioTherapeutics Holdings Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

EPS (Diluted)

-280.28

-2,143.68

-313.50

-150.52

-18.14

Sonnet BioTherapeutics Holdings Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial												-17.62	-7.48	-2.86	-2.10	-0.31

Competitive Comparison of Sonnet BioTherapeutics Holdings's EPS (Diluted)

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonnet BioTherapeutics Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's PE Ratio falls into.

Sonnet BioTherapeutics Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sonnet BioTherapeutics Holdings's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-18.833	-	0)	/	1.038
	=	-18.14

Sonnet BioTherapeutics Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.169	-	0)	/	3.798
	=	-0.31

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.75

Sonnet BioTherapeutics Holdings (NAS:SONN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sonnet BioTherapeutics Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540

Website

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Executives

John Markey	10 percent owner	10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter	officer: Chief Technical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan	director, officer: Chairman, President and CEO	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney	officer: Chief Medical Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg	officer: Chief Medical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini	officer: Chief Scientific Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii	officer: Chief Financial Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc	10 percent owner	918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701